Effect of the COVID-19 pandemic on diagnoses and therapy of head and neck squamous cell carcinoma

Recruiting

• Conditions: C00-C14; C32; C76.0; C76.7; C76.8; Malignant neoplasms of lip, oral cavity and pharynx; Malignant neoplasm of larynx; Head, face and neck; Other ill-defined sites; Overlapping lesion of other and ill-defined sites

• Registration Number: DRKS00031558
• Lead Sponsor: Klinik und Poliklinik für Hals-Nasen-Ohren-Heilkunde, Universitätsklinikum Regensburg

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2023-03-27
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 20000

Inclusion Criteria

Head and neck squamous cell carcinoma (HNSCC)

Exclusion Criteria

None

Study & Design

• Study Type: observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Incidence of newly diagnosed head and neck squamous cell carcinoma (HNSCC)

Secondary Outcome Measures

Name	Time	Method
Tumour stage, primary treatment modality, time interval between diagnosis and initiation of tumour therapy.